Ruixin Medical's Coronary Interventional Surgery Control System Selected for China's 2025 AI Medical Device Innovation Initiative
RaysightMed
Medical Imaging Product Developer
On December 8, the Ministry of Industry and Information Technology and the National Medical Products Administration announced the shortlisted entities for the "2025 Artificial Intelligence Medical Device Innovation Task."RaysightMed's self-developed "Coronary Artery Interventional Surgery Control System" successfully entered the shortlist for intelligent auxiliary decision-making product direction, thanks to its leading innovation capability and clinical value.。
To implement the important instructions and directives on the development of artificial intelligence, promote the deep integration of artificial intelligence technology with medical devices, better serve and safeguard the life and health of the people, and accelerate the formation of new quality productivity, the Ministry of Industry and Information Technology and the National Medical Products Administration jointly launched the 2025 AI Medical Device Innovation Task under the "Open Challenge" initiative. Focusing on three major categories and nine challenge directions—intelligent decision support products, brain-computer hybrid intelligent products, and supporting environments—this initiative...Solicit and select a group of units with strong innovation capabilities to focus on research, promote the innovative development of artificial intelligence medical devices, and accelerate the implementation of new technologies and products.。
The "Coronary Artery Intervention Surgical Control System" by RaysightMed that made it to the shortlist this time,It is an intelligent surgical assistance system applied in percutaneous coronary intervention (PCI). The system is suitable for patients with coronary artery disease who need to undergo PCI surgery.The doctor precisely controls the surgical instruments through a master-slave control system to complete interventional surgical procedures.。
The system is mainly composed ofEndo-surgical Platform(Including instrument transmission device and mechanical arm) andMaster Control PlatformComposition. Doctors can operate through the joystick or touch screen at the master end in the control room, enabling real-time and precise control of the advancement, retraction, and rotation of guiding catheters, guidewires, balloon/stent catheters, and other instruments, thereby assisting in completing key PCI steps such as balloon dilation and stent deployment.
Percutaneous Coronary Intervention (PCI) is currently the most important and effective interventional treatment method for coronary heart disease. Data shows that the number of PCI procedures in China has increased from 1.164 million in 2021 to 1.911 million in 2024. Market forecasts predict that by 2030, the number of PCI procedures in China is expected to exceed 3.6 million.
However, traditional PCI procedures still face many challenges: high operational difficulty, long procedure times, doctors need to be exposed to X-ray radiation for extended periods, and the success rate of the surgery is influenced by various factors. In addition, the distribution of medical resources in China is uneven, and the interventional surgery capabilities in many regions need to be urgently improved.
RaysightMed's Coronary Interventional Surgery Control System is specifically designed to address these pain points. It is capable of:
Help Doctors Stay Away from Radiation, avoiding the burden of lead aprons and enhancing occupational health protection;
Achieve precise surgical navigation during surgeryAnd success rate;
Assist less experienced doctors in completing complex surgeries, reducing the learning threshold and operational difficulty of interventional procedures;
Improve the Overall Success Rate and Accessibility of Surgery, helping high-quality medical resources reach lower levels.
As of now,RaysightMed Coronary Interventional Surgery Control SystemMore than 20 patents have been applied for, and the product has completed prototyping, registration testing, dozens of animal experiments, and more than ten clinical trial validations. The safety, effectiveness, and precision of the surgical robot system in performing coronary PCI procedures instead of human hands have been preliminarily verified.
The inclusion in the national-level artificial intelligence medical device innovation mission is a full affirmation of RaysightMed's technological innovation capabilities and the clinical value of its products. RaysightMed will continue to focus on precise cardiac AI and robotic interventions.IntegrationThe research, development, and application of the platform promote the independent control of high-end medical equipment, empower doctors, and create a safer and more efficient diagnosis and treatment future for patients.
